King Pharmaceuticals KG Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Leverage | ||||||
| Debt-to-equity | 1.5×+0.1× | 1.4×+0.1× | 1.2×+0.1× | 1.2×— | —— | |
| Per Share | ||||||
| Book value per share | $15.66-30.0% | $22.38+20.5% | $18.57-42.6% | $32.38+2,006% | $1.54-8.2% | |
| Valuation | ||||||
| Market capitalization | $70.42M-71.3% | $79.28M-62.5% | $211.43M-15.0% | $248.69M— | —— | |
| Price / sales | 1.6×-27.7× | 2.3×-6.1× | 8.4×-21.3× | 29.7×— | —— | |
| Price / book | 0.6×-1.1× | 0.6×-0.9× | 1.5×-0.2× | 1.7×— | —— |
Questions, answered.
- Where do King Pharmaceuticals's ratios come from?
- Every ratio is computed from King Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
